US FDA’s Marks Worries Someone May Stop Hybrid Work System
Executive Summary
CBER Director Peter Marks said the FDA’s remote and in-person work system is functioning well and continues to help recruitment.
You may also be interested in...
US FDA’s Gene Therapy Office Director Nicole Verdun Must Fill Other Roles As Well
Until hiring is completed, the new Office of Therapeutic Products director must head an office and two divisions she supervises in addition to her actual duties.
Peter Marks’ Fears May Come True: White House Wants More In-Person Work
The CBER director has worried that ‘someone’ might try to end the US FDA’s hybrid work policy. Now the push against it is bipartisan.
US FDA Implementing Hybrid Work Policy In January
Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.